Pharmacyte Biotech Inc (OTCMKTS:PMCB) disclosed that the Chairman of Scientific Advisory Board, Dr. Matthias Lohr along with Dr. Manuel Hidalgo will work together with other known oncologists from the Spain, U.K., Italy, Belgium and Germany in co-authoring an important review article covering pancreatic cancer. This article, which was featured in the scientific journal Pancreatology, highlights the major issues linked with the cure of Pancreatic Cancer and the future measures to achieve better results.
Pharmacyte stated that the article focal point was pancreatic ductal adenocarcinoma which comprises over 90% of total reported pancreatic cancers. All the statistics and the problems related to PDAC are mentioned and the development plans are detailed. Of prime importance is the assessment of current treatment alternatives for locally advanced and surgical PDAC.
Sanofi SA (ADR)(NYSE:SNY) Updates On Deal With Relypsa Inc (NASDAQ:RLYP)
Relypsa Inc (NASDAQ:RLYP) disclosed that it entered into a two-year detailing agreement with Sanofi SA (ADR)(NYSE:SNY) for its investigational medication ‘Patiromer FOS’. The drug is currently under assessment for hyperkalemia treatment with the U.S. FDA, with a PDUFA action expecting in October 2015.
Relypsa intends to initiate commercialization of Patiromer FOS after the regulatory approval. It will launch the commercialization plan with its specialty sales force and commercial team of almost 120 members. This specialized team will try to extend their outreach to hospitals, cardiologists and nephrologists.
After recording strong gains on Thursday, the share price of Pfizer Inc. (NYSE:PFE) is heading south on the chart. It recorded gains after the company confirmed the initiation of a global phase III study on its breast cancer drug, known as ‘Ibrance’. The announced study will be initiated with an objective of assessing the impact of drug on disease-free survival rate, when it is complemented with standard care of treatment.